Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial-Reference-Cited by-同舟云学术

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Published:2017-03 Issue:3 Volume:4 Page:e127-e136
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Oliva Esther N,Alati Caterina,Santini Valeria,Poloni Antonella,Molteni Alfredo,Niscola Pasquale,Salvi Flavia,Sanpaolo Grazia,Balleari Enrico,Germing Ulrich,Fenaux Pierre,Stamatoullas Aspasia,Palumbo Giuseppe A,Salutari Prassede,Impera Stefana,Avanzini Paolo,Cortelezzi Agostino,Liberati Anna Marina,Carluccio Paola,Buccisano Francesco,Voso Maria Teresa,Mancini Stefano,Kulasekararaj Austin,Morabito Fortunato,Bocchia Monica,Cufari Patrizia,Spiriti Maria Antonietta Aloe,Santacaterina Irene,D'Errigo Maria Grazia,Bova Irene,Zini Gina,Latagliata Roberto

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Myelodysplastic syndromes/neoplasms, overview;Brunning,2008

2. The incidence and impact of thrombocytopenia in myelodysplastic syndromes;Kantarjian;Cancer,2007

3. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome;Gonzalez-Porras;Cancer,2011

4. A prognostic score for patients with lower risk myelodysplastic syndrome;Garcia-Manero;Leukemia,2008

5. Revised international prognostic scoring system for myelodysplastic syndromes;Greenberg;Blood,2012

Cited by 142 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities;Current Hematologic Malignancy Reports;2024-04-18

2. Role of reactive oxygen species in myelodysplastic syndromes;Cellular & Molecular Biology Letters;2024-04-14

3. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape;Current Oncology;2024-04-03

4. Novel Perspectives on Thrombopoietin Receptor Agonists Applications;Hämostaseologie;2024-03-18

5. Clinical Outcomes, Survival, and Predictors in Lower-Risk Myelodysplastic Syndrome Patients Treated with Cyclosporine A;Acta Haematologica;2024-02-17